A randomized, double-blind, placebo-controlled study on addition of infliximab to the FIN-RACO DMARD combination therapy for initial six months in patients with early active rheumatoid arthritis. The NEO-RACO study. - Leirisalo-Repo M, Kautiainen,H.; Laasonen,L.; Möttönen,T. (Ann Rheum Dis, 2008)